Evaluation of MHC class I peptide binding prediction servers: Applications for vaccine research

BackgroundProtein antigens and their specific epitopes are formulation targets for epitope-based vaccines. A number of prediction servers are available for identification of peptides that bind major histocompatibility complex class I (MHC-I) molecules. The lack of standardized methodology and large number of human MHC-I molecules make the selection of appropriate prediction servers difficult. This study reports a comparative evaluation of thirty prediction servers for seven human MHC-I molecules.ResultsOf 147 individual predictors 39 have shown excellent, 47 good, 33 marginal, and 28 poor ability to classify binders from non-binders. The classifiers for HLA-A*0201, A*0301, A*1101, B*0702, B*0801, and B*1501 have excellent, and for A*2402 moderate classification accuracy. Sixteen prediction servers predict peptide binding affinity to MHC-I molecules with high accuracy; correlation coefficients ranging from r = 0.55 (B*0801) to r = 0.87 (A*0201).ConclusionNon-linear predictors outperform matrix-based predictors. Most predictors can be improved by non-linear transformations of their raw prediction scores. The best predictors of peptide binding are also best in prediction of T-cell epitopes. We propose a new standard for MHC-I binding prediction – a common scale for normalization of prediction scores, applicable to both experimental and predicted data. The results of this study provide assistance to researchers in selection of most adequate prediction tools and selection criteria that suit the needs of their projects.

[1]  D. Cox,et al.  An Analysis of Transformations , 1964 .

[2]  J A Swets,et al.  Measuring the accuracy of diagnostic systems. , 1988, Science.

[3]  H. Rammensee,et al.  Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast , 1991, The Journal of experimental medicine.

[4]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.

[5]  J. Coligan,et al.  Presentation of three different viral peptides, HTLV-1 Tax, HCMV gB, and influenza virus M1, is determined by common structural features of the HLA-A2.1 molecule. , 1992, Journal of immunology.

[6]  D. Wiley,et al.  The antigenic identity of peptide-MHC complexes: A comparison of the conformations of five viral peptides presented by HLA-A2 , 1993, Cell.

[7]  J. Berzofsky,et al.  An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans , 1994, Journal of virology.

[8]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[9]  S. Stacey,et al.  Human cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (A*0201) motif. , 1994, Immunology.

[10]  S. Burrows,et al.  Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. , 1994, The Journal of general virology.

[11]  Don C. Wiley,et al.  Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.

[12]  A. Samri,et al.  CTLs from lymphoid organs recognize an optimal HLA-A2-restricted and HLA-B52-restricted nonapeptide and several epitopes in the C-terminal region of HIV-1 Nef. , 1995, Journal of immunology.

[13]  F. Chisari,et al.  Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. , 1995, The Journal of clinical investigation.

[14]  H. Rammensee,et al.  Chemistry of peptides associated with MHC class I and class II molecules. , 1995, Current opinion in immunology.

[15]  V. Engelhard,et al.  Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice. , 1995, International immunology.

[16]  J. Berzofsky,et al.  CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. , 1995, Journal of immunology.

[17]  J. Berzofsky,et al.  Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules , 1995, Journal of virology.

[18]  F. Marincola,et al.  Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35) , 1996, The Journal of experimental medicine.

[19]  R P Johnson,et al.  Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes , 1996, Journal of virology.

[20]  L. Fugger,et al.  Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[21]  B. Walker,et al.  Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. , 1996, Journal of immunology.

[22]  A. Rickinson,et al.  Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. , 1997, Journal of immunology.

[23]  A. Sette,et al.  Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. , 1997, Cancer research.

[24]  A. Kumar,et al.  Immediate Early and Early Lytic Cycle Proteins Are Frequent Targets of the Epstein-Barr Virus–induced Cytotoxic T Cell Response , 1997, The Journal of experimental medicine.

[25]  R. Khanna,et al.  Identification of a Cytotoxic T-Lymphocyte Response to the Novel BARF0 Protein of Epstein-Barr Virus: a Critical Role for Antigen Expression , 1998, Journal of Virology.

[26]  S. Burrows,et al.  Identification of cytotoxic T cell epitopes within Epstein‐Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype‐restricted immune recognition of EBV‐infected cells by LMP1‐specific cytotoxic T lymphocytes , 1998, European journal of immunology.

[27]  S. Burrows,et al.  EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. , 1999, Journal of Immunology.

[28]  A Sette,et al.  Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. , 1999, Journal of immunology.

[29]  J A Madrigal,et al.  Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. , 1999, Journal of immunology.

[30]  R. Offringa,et al.  Differential binding of viral peptides to HLA‐A2 alleles. Implications for human papillomavirus type 16 E7 peptide‐based vaccination against cervical carcinoma , 1999, European journal of immunology.

[31]  U. Şahin,et al.  Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.

[32]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[33]  P R Kolatkar,et al.  Knowledge-based grouping of modeled HLA peptide complexes. , 2000, Human immunology.

[34]  Dominique Charron,et al.  HLA-DR Restricted Peptide Candidates for Bee Venom Immunotherapy , 2000, The Journal of Immunology.

[35]  O. Schueler‐Furman,et al.  Structure‐based prediction of binding peptides to MHC class I molecules: Application to a broad range of MHC alleles , 2000, Protein science : a publication of the Protein Society.

[36]  B. Bodey,et al.  Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. , 2000, Anticancer research.

[37]  F. Lemonnier,et al.  A general strategy to enhance immunogenicity of low‐affinity HLA‐A2.1‐associated peptides: implication in the identification of cryptic tumor epitopes , 2000, European journal of immunology.

[38]  H. Grey,et al.  Epitope affinity for MHC class I determines helper requirement for CTL priming , 2000, Nature Immunology.

[39]  Maria V. Tejada-Simon,et al.  Naturally Processed HLA Class II Peptides Reveal Highly Conserved Immunogenic Flanking Region Sequence Preferences That Reflect Antigen Processing Rather Than Peptide-MHC Interactions1 , 2001, The Journal of Immunology.

[40]  Gajendra P. S. Raghava,et al.  ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..

[41]  Vladimir Brusic,et al.  Computational immunology: The coming of age , 2002, Immunology and cell biology.

[42]  P. Coulie,et al.  A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. , 2002, Cancer research.

[43]  Forest M White,et al.  Analysis of MHC Class II Antigen Processing by Quantitation of Peptides that Constitute Nested Sets , 2002, The Journal of Immunology.

[44]  Thierry Boon,et al.  Tumor‐specific shared antigenic peptides recognized by human T cells , 2002, Immunological reviews.

[45]  Kun Yu,et al.  Methods for Prediction of Peptide Binding to MHC Molecules: A Comparative Study , 2002, Molecular medicine.

[46]  S. Rosenberg,et al.  Identification of BING-4 Cancer Antigen Translated From an Alternative Open Reading Frame of a Gene in the Extended MHC Class II Region Using Lymphocytes From a Patient With a Durable Complete Regression Following Immunotherapy , 2002, The Journal of Immunology.

[47]  D. Schadendorf,et al.  Identification of known and novel immunogenic T‐cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL‐2‐based treatment , 2002, International journal of cancer.

[48]  Hans-Georg Rammensee,et al.  Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  P. Moss,et al.  Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. , 2002, The Journal of infectious diseases.

[50]  E. Reinherz,et al.  Prediction of MHC class I binding peptides using profile motifs. , 2002, Human immunology.

[51]  M. Sathiamurthy,et al.  Population of the HLA ligand database. , 2003, Tissue antigens.

[52]  Gajendra P. S. Raghava,et al.  ProPred1: Prediction of Promiscuous MHC Class-I Binding Sites , 2003, Bioinform..

[53]  S Brunak,et al.  Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. , 2003, Tissue antigens.

[54]  Daniel Gillet,et al.  The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells. , 2003, Cancer research.

[55]  J. Muche,et al.  Anti‐tumor immune responses and tumor regression induced with mimotopes of a tumor‐associated T cell epitope , 2003, European journal of immunology.

[56]  J. Ehreth,et al.  The value of vaccination: a global perspective. , 2003, Vaccine.

[57]  S. Menzies,et al.  Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma , 2004, Cancer Immunology, Immunotherapy.

[58]  Vladimir Brusic,et al.  MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  P. Kloetzel,et al.  MAPPP: MHC class I antigenic peptide processing prediction. , 2003, Applied bioinformatics.

[60]  Ken Jung,et al.  Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[61]  M. Kuroda,et al.  Low Frequency of Cytotoxic T Lymphocytes against the Novel HLA-A*0201-Restricted JC Virus Epitope VP1p36 in Patients with Proven or Possible Progressive Multifocal Leukoencephalopathy , 2003, Journal of Virology.

[62]  Bjoern Peters Modeling the MHC-I pathway , 2003 .

[63]  J. Shabanowitz,et al.  The minor Histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein , 2003 .

[64]  John Sidney,et al.  Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules , 2003, Bioinform..

[65]  O. Lund,et al.  novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .

[66]  Gajendra P. S. Raghava,et al.  SVM based method for predicting HLA-DRB1*0401 binding peptides in an antigen sequence , 2004, Bioinform..

[67]  Vladimir Brusic,et al.  Computational methods for prediction of T-cell epitopes--a framework for modelling, testing, and applications. , 2004, Methods.

[68]  H. Rammensee,et al.  Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire , 2004, Cellular and Molecular Life Sciences CMLS.

[69]  H. Rammensee,et al.  Induction of Adipophilin-Specific Cytotoxic T Lymphocytes Using a Novel HLA-A2-Binding Peptide That Mediates Tumor Cell Lysis , 2004, Cancer Research.

[70]  E. Bissonette,et al.  Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Vladimir Brusic,et al.  Pathogenic human thyroglobulin peptides in HLA-DR3 transgenic mouse model of autoimmune thyroiditis. , 2004, Cellular immunology.

[72]  M. von Knebel Doeberitz,et al.  Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. , 2004, Cancer immunity.

[73]  H. Yamana,et al.  Phase I trial of patient‐oriented vaccination in HLA‐A2‐positive patients with metastatic hormone‐refractory prostate cancer , 2004, Cancer science.

[74]  Søren Brunak,et al.  Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach , 2004, Bioinform..

[75]  Bjoern Peters,et al.  HLA-A*0201, HLA-A*1101, and HLA-B*0702 transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products. , 2005, The Journal of Immunology.

[76]  Alessandro Sette,et al.  Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method , 2005, BMC Bioinformatics.

[77]  Hyeoncheol Kim,et al.  Prediction Rule Generation of MHC Class I Binding Peptides Using ANN and GA , 2005, ICNC.

[78]  Vladimir Brusic,et al.  MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides , 2005, Nucleic Acids Res..

[79]  Steve Wilson,et al.  The Immune Epitope Database and Analysis Resource: From Vision to Blueprint , 2005, PLoS biology.

[80]  Francisco A. Chaves,et al.  The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes , 2005, Immunological reviews.

[81]  Vladimir Brusic,et al.  Information technologies for vaccine research , 2005, Expert review of vaccines.

[82]  Bjoern Peters,et al.  HLA-A*0201, HLA-A*1101, and HLA-B*0702 Transgenic Mice Recognize Numerous Poxvirus Determinants from a Wide Variety of Viral Gene Products1 , 2005, The Journal of Immunology.

[83]  O. Lund,et al.  An integrative approach to CTL epitope prediction: A combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions , 2005, European journal of immunology.

[84]  Bjoern Peters,et al.  Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications , 2005, Immunogenetics.

[85]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[86]  Lonce L. Wyse,et al.  Deriving Matrix of Peptide-MHC Interactions in Diabetic Mouse by Genetic Algorithm , 2005, IDEAL.

[87]  L. Tussey,et al.  Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles. , 2005, Cancer immunity.

[88]  Markus Weininger,et al.  Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin , 2006, Cancer Immunology, Immunotherapy.

[89]  Jukka Partanen,et al.  T Cell Epitope-Containing Peptides of the Major Dog Allergen Can f 1 as Candidates for Allergen Immunotherapy1 , 2005, The Journal of Immunology.

[90]  Karina Yusim,et al.  Immunoinformatics Comes of Age , 2006, PLoS Comput. Biol..

[91]  Tin Wee Tan,et al.  Structural bioinformatics Prediction of HLA-DQ 3 . 2 b Ligands : evidence of multiple registers in class II binding peptides , 2006 .

[92]  Marij J P Welters,et al.  Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. , 2006, Advanced drug delivery reviews.

[93]  Channa K. Hattotuwagama,et al.  MHCPred 2.0 , 2006 .

[94]  Z. Cao,et al.  MHC-BPS: MHC-binder prediction server for identifying peptides of flexible lengths from sequence-derived physicochemical properties , 2006, Immunogenetics.

[95]  Emil R Unanue,et al.  The wide diversity and complexity of peptides bound to class II MHC molecules. , 2006, Current opinion in immunology.

[96]  Shisong Jiang,et al.  Overlapping synthetic peptides as vaccines , 2006, Vaccine.

[97]  Chee Keong Kwoh,et al.  Extreme Learning Machine for Predicting HLA-Peptide Binding , 2006, ISNN.

[98]  Morten Nielsen,et al.  A Community Resource Benchmarking Predictions of Peptide Binding to MHC-I Molecules , 2006, PLoS Comput. Biol..

[99]  John Sidney,et al.  Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients , 2006, AIDS.

[100]  Fang-Xiang Wu,et al.  Optimally-connected Hidden Markov Models for Predicting Mhc-binding Peptides , 2006, J. Bioinform. Comput. Biol..

[101]  Darren R. Flower,et al.  Predicting Class II MHC-Peptide binding: a kernel based approach using similarity scores , 2006, BMC Bioinformatics.

[102]  Sylvie C. Fail,et al.  The IMGT/HLA and IPD databases , 2006, Human mutation.

[103]  Yoram Louzoun,et al.  T-cell epitope repertoire as predicted from human and viral genomes. , 2006, Molecular immunology.

[104]  Ora Schueler-Furman,et al.  Learning MHC I - peptide binding , 2006, ISMB.

[105]  Oliver Kohlbacher,et al.  SVMHC: a server for prediction of MHC-binding peptides , 2006, Nucleic Acids Res..

[106]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[107]  D. DeLuca,et al.  A modular concept of HLA for comprehensive peptide binding prediction , 2006, Immunogenetics.

[108]  V. Apostolopoulos,et al.  Design of peptide-based vaccines for cancer. , 2006, Current medicinal chemistry.

[109]  I. Svane,et al.  Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. , 2006, European urology.

[110]  Thomas Lengauer,et al.  DynaPred: A structure and sequence based method for the prediction of MHC class I binding peptide sequences and conformations , 2006, ISMB.

[111]  Tomer Hertz,et al.  PepDist: A New Framework for Protein-Peptide Binding Prediction based on Learning Peptide Distance Functions , 2006, BMC Bioinformatics.

[112]  Channa K. Hattotuwagama,et al.  MHCPred 2.0: an updated quantitative T-cell epitope prediction server. , 2006, Applied bioinformatics.

[113]  Loris Nanni,et al.  Machine learning algorithms for T-cell epitopes prediction , 2006, Neurocomputing.

[114]  Marylène Lejeune,et al.  Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  J. Reimann,et al.  Complexes of DNA vaccines with cationic, antigenic peptides are potent, polyvalent CD8(+) T-cell-stimulating immunogens. , 2006, Methods in Molecular Medicine.

[116]  Ji Wan,et al.  SVRMHC prediction server for MHC-binding peptides , 2006, BMC Bioinformatics.

[117]  Steven G E Marsh,et al.  The IMGT/HLA database. , 2007, Methods in molecular biology.

[118]  N. Kallinteris,et al.  Induction of potent CD4+ T cell‐mediated antitumor responses by a helper HER‐2/neu peptide linked to the Ii‐Key moiety of the invariant chain , 2007, International journal of cancer.

[119]  I. Bozic,et al.  Prediction of supertype-specific HLA class I binding peptides using support vector machines. , 2007, Journal of immunological methods.

[120]  Anthony Kusalik,et al.  Strength in numbers: achieving greater accuracy in MHC-I binding prediction by combining the results from multiple prediction tools , 2007, Immunome research.

[121]  Bernard Maillere,et al.  HLA-DR-restricted peptides identified in the Nef protein can induce HIV type 1-specific IL-2/IFN-gamma-secreting CD4+ and CD4+ /CD8+ T cells in humans after lipopeptide vaccination. , 2007, AIDS research and human retroviruses.

[122]  Tin Wee Tan,et al.  In silico characterization of immunogenic epitopes presented by HLA-Cw*0401 , 2007, Immunome research.

[123]  J. Banga,et al.  Application of HLA class II transgenic mice to study autoimmune regulation. , 2007, Thyroid : official journal of the American Thyroid Association.

[124]  Leonard Moise,et al.  Prediction of immunogenicity for therapeutic proteins: state of the art. , 2007, Current opinion in drug discovery & development.

[125]  K. Hirata,et al.  Efficient Cross-Presentation by Heat Shock Protein 90-Peptide Complex-Loaded Dendritic Cells via an Endosomal Pathway , 2007, The Journal of Immunology.

[126]  R. Kennedy,et al.  T‐Cell epitope discovery for variola and vaccinia viruses , 2007, Reviews in medical virology.

[127]  R. Tampé,et al.  Identification of a Lysosomal Peptide Transport System Induced during Dendritic Cell Development* , 2007, Journal of Biological Chemistry.

[128]  R. Rappuoli,et al.  The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials. , 2007, Drug discovery today.

[129]  David Heckerman,et al.  Leveraging Information Across HLA Alleles/Supertypes Improves Epitope Prediction , 2007, J. Comput. Biol..

[130]  Lei Huang,et al.  A probabilistic meta-predictor for the MHC class II binding peptides , 2007, Immunogenetics.

[131]  T. Reinheckel,et al.  A Transporter Associated with Antigen-Processing Independent Vacuolar Pathway for the MHC Class I-Mediated Presentation of Endogenous Transmembrane Proteins , 2007, The Journal of Immunology.

[132]  James McCluskey,et al.  More than one reason to rethink the use of peptides in vaccine design , 2007, Nature Reviews Drug Discovery.

[133]  L. Stern,et al.  Human CD4+ T Cell Epitopes from Vaccinia Virus Induced by Vaccination or Infection , 2007, PLoS pathogens.

[134]  Matthew N Davies,et al.  Harnessing bioinformatics to discover new vaccines. , 2007, Drug discovery today.

[135]  Gajendra P.S. Raghava,et al.  A hybrid approach for predicting promiscuous MHC class I restricted T cell epitopes , 2007, Journal of Biosciences.

[136]  Rainer Blasczyk,et al.  Implementing the modular MHC model for predicting peptide binding. , 2007, Methods in molecular biology.

[137]  Tomer Hertz,et al.  Identifying HLA supertypes by learning distance functions , 2007, Bioinform..

[138]  C. Akdis,et al.  Targeting the MHC II presentation pathway in allergy vaccine development. , 2007, Biochemical Society transactions.

[139]  Claude Auriault,et al.  Determination of a HLA II Promiscuous Peptide Cocktail as Potential Vaccine Against EBV Latency II Malignancies , 2007, Journal of immunotherapy.

[140]  G. Parmiani,et al.  Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials1 , 2007, The Journal of Immunology.

[141]  R. Naz,et al.  Peptide vaccines against cancer, infectious diseases, and conception. , 2007, Frontiers in bioscience : a journal and virtual library.

[142]  Zhao-You Tang,et al.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  Morten Nielsen,et al.  Modeling the adaptive immune system: predictions and simulations , 2007, Bioinform..

[144]  Tin Wee Tan,et al.  Evolutionarily Conserved Protein Sequences of Influenza A Viruses, Avian and Human, as Vaccine Targets , 2007, PloS one.

[145]  Morten Nielsen,et al.  Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method , 2007, BMC Bioinformatics.

[146]  P. Sabbatini,et al.  Immunologic approaches to ovarian cancer treatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[147]  Tin Wee Tan,et al.  Methods and protocols for prediction of immunogenic epitopes , 2006, Briefings Bioinform..

[148]  Tin Wee Tan,et al.  Conservation and Variability of Dengue Virus Proteins: Implications for Vaccine Design , 2008, PLoS neglected tropical diseases.

[149]  Uthaman Gowthaman,et al.  In silico tools for predicting peptides binding to HLA-class II molecules: more confusion than conclusion. , 2008, Journal of proteome research.

[150]  Morten Nielsen,et al.  Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan , 2008, PLoS Comput. Biol..

[151]  E. Tartour,et al.  Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients1 , 2008, The Journal of Immunology.

[152]  John Sidney,et al.  A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..

[153]  黒瀧 武洋 Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway , 2008 .

[154]  Clemencia Pinilla,et al.  Thyroglobulin Peptides Associate In Vivo to HLA-DR in Autoimmune Thyroid Glands1 , 2008, The Journal of Immunology.

[155]  Bjoern Peters,et al.  Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries , 2008, Immunome research.

[156]  S. Lee,et al.  HLA A 2 . 1-Restricted Cytotoxic T Cells Recognizing a Range of Epstein-Barr Virus Isolates through a Defined Epitope in Latent Membrane Protein LMP 2 , 2022 .